Pharmacodynamics of High-Dose Chemotherapy

Author: Netio Y.

Source: Current Drug Metabolism, Volume 2, Number 1, March 2001 , pp. 53-66(14)

Publisher: Bentham Science Publishers

Key:

- Free Content

- New Content

- Subscribed Content

- Free Trial Content

Abstract:

There is usually considerable variability in anticancer drug plasma levels when delivered at high doses requiring stem-cell support. Given their narrow therapeutic windows and wide interpatient pharmacokinetic variability, drug monitoring and pharmacokinetic-directed dosing represent an attractive strategy in this setting. A major previous requirement to successful application of therapeutic drug monitoring is identification of a significant and clinically meaningful pharmacodynamic correlation between a pharmacokinetic parameter and a toxic or therapeutic outcome, or preferably, both. In this review, we will analyze the current knowledge of identified pharmacodynamic correlations in high-dose chemotherapy. We will summarize the observations from other authors and our own, on drugs employed at high doses, such as cyclophosphamide, melphalan, busulfan, carmustine, paclitaxel, or docetaxel.

Keywords: Pharmacodynamics High-Dose Chemotherapy; anticancer drug plasma levels; cyclophosphamide; melphalan; busulfan; carmustine; paclitaxel; docetaxel; docetaxel

Language: English

Document Type: Review article

DOI: 10.2174/1389200013338720

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$55.10 plus tax Refund Policy